Nu-Med Plus Inc. (NUMD:OTC.MKTS) launched a rebrand that distinguishes it as an industry leader that is "reinventing the healing power of nitric oxide delivery," according to the company.
The mission of this medical device company is to "explore medical applications of newly developed nitric oxide technologies," the company also noted. It currently has a pipeline of four products and is designing and building the next generation of nitric oxide delivery systems, which should boast higher precision and lower cost.
"The nitric oxide delivery landscape is changing, and our innovative approach, proven technology and more precise engineering is targeted at exceptional growth potential," said CEO Jeff Robins in a news release.
The purpose of the strategic rebranding is to highlight Nu-Med Plus' primary objective, its patented technology and its cutting-edge advancements in the industry. The new positioning is evident, in part, on the company's revamped website Nu-MedPlus.com, in its LinkedIn profile and via its Twitter feed @NuMedPlus.
"Explore our new online presence to see how we're changing the future of nitric oxide delivery," Robins added.
Nu-Med Plus' product pipeline includes three devices that would become available commercially following U.S. Food and Drug Administration approval. They are a hospital unit designed for ventilated inpatients; a clinical unit for emergency rooms, nursing homes and clinics; and a lightweight, portable unit for quick response anywhere. The company's Nu-Med Plus 100 is a nitric oxide dilution system built for and currently being used in academic research.
With its existing and in-development technology, the company aims to "disrupt current markets and open new markets," said Robins. "Those markets, in the treatment of malaria, chronic obstructive pulmonary disease, tuberculosis, acute respiratory distress syndrome and wound healing, present billions of dollars in annual value and, more importantly, present the potential to save and better millions of lives."
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Nu-Med Plus. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
